W3C home > Mailing lists > Public > public-semweb-lifesci@w3.org > August 2012

RE: seeks input on Study Data Exchange Standards

From: Mead, Charlie (NIH/NCI) [C] <meadch@mail.nih.gov>
Date: Fri, 17 Aug 2012 07:30:39 -0400
To: Kerstin Forsberg <kerstin.l.forsberg@gmail.com>, Eric Prud'hommeaux <eric@w3.org>, Michel Dumontier <michel.dumontier@gmail.com>
CC: HCLS hcls <public-semweb-lifesci@w3.org>
Message-ID: <4D241B2CAA657641A30147AA5BF6AE782BA5D71F4B@NIHMLBX07.nih.gov>
Hi Kerstin --

That does sound like a good plan, in particular because Eric and I will have attended the September HL7 Working Group meeting and will thus have the latest updates of progress and challenges.

charlie
________________________________________
From: Kerstin Forsberg [kerstin.l.forsberg@gmail.com]
Sent: Friday, August 17, 2012 2:25 AM
To: Mead, Charlie (NIH/NCI) [C]; Eric Prud'hommeaux; Michel Dumontier
Cc: HCLS hcls
Subject: Re: seeks input on Study Data Exchange Standards

Great to see the feedback from several people on this list with interesting references.

Charlie, Eric and Michel
I strugle a bit with setup of HCLS-IG calls. Could this be a topic on a coming call? Given the vacation period and the deadline for response, 5th Oct, do you think this is doable?

Regards
Kerstin




15 aug 2012 kl. 08:01 skrev "Mead, Charlie (NIH/NCI) [C]" <meadch@mail.nih.gov>:

> I would say Yes -- particularly since there is now an effort to represent some of newest HL7 standards -- FHIR resource definitions in particular -- using SW approaches...and the BRIDG OWL representation will almost certainly benefit from this effort.
>
> charlie
> ________________________________________
> From: Kerstin Forsberg [kerstin.l.forsberg@gmail.com]
> Sent: Wednesday, August 15, 2012 1:57 AM
> To: HCLS hcls
> Subject: FDA: seeks input on Study Data Exchange Standards
>
> FDA seeks "input from industry, technology vendors, and other members of the public regarding the advantages and disadvantages of current and emerging open, consensus-based standards for the exchange of regulated study data. "
>
> In the annoncement for a meeting 5 November FDA ask for responses, before 5 October, on questions such as "- What are the advantages and disadvantages of HL7 v3 and CDISC ODM?"
>
> And, interestingly, they also ask: "- Are there other open data exchange standards that should be evaluated?"
>
> Is this an opportunity for a semantic web based proposal?
>
> Kind Regards
>
> Kerstin Forsberg
>
> AstraZeneca
>
>
>
> https://www.federalregister.gov/articles/2012/08/14/2012-19748/regulatory-new-drug-review-solutions-for-study-data-exchange-standards-notice-of-meeting-request-for
Received on Friday, 17 August 2012 11:32:03 GMT

This archive was generated by hypermail 2.3.1 : Tuesday, 26 March 2013 18:01:12 GMT